Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Still a Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped up prior to trading on Wednesday . The stock had previously closed at $30.58, but opened at $33.65. Nanobiotix shares last traded at $33.04, with a volume of 8,075 shares trading hands.

Analysts Set New Price Targets

Several research analysts have issued reports on NBTX shares. Guggenheim raised their price target on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. TD Cowen assumed coverage on shares of Nanobiotix in a report on Friday, February 6th. They set a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Nanobiotix Stock Down 6.8%

The firm has a fifty day moving average price of $23.68 and a 200-day moving average price of $20.01.

Institutional Investors Weigh In On Nanobiotix

Several large investors have recently made changes to their positions in the business. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the last quarter. Optiver Holding B.V. bought a new position in Nanobiotix during the third quarter valued at about $101,000. Marshall Wace LLP purchased a new stake in Nanobiotix during the fourth quarter worth about $220,000. Finally, Millennium Management LLC bought a new stake in Nanobiotix in the fourth quarter worth about $390,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.